- Bora Biologics has appointed Jennifer Kuan as chief executive officer to lead the company’s next phase of development.
- The company plans to strengthen its global capabilities and continue supporting customers from biologics development through commercialization.
Bora Biologics has appointed Jennifer Kuan as chief executive officer, placing her in charge of the company’s next phase of development. Kuan brings leadership experience across biologics, contract development and manufacturing organization (CDMO) operations, customer partnerships, and organizational growth.
In her new role, Kuan will lead the company’s efforts to build on its existing capabilities in scientific development, operational quality, and customer-focused biologics manufacturing. Bora Biologics said it intends to continue strengthening its global capabilities and supporting customers throughout the development and commercialization process.
The appointment reflects the company’s focus on expanding its biologics manufacturing capabilities and helping customers advance products toward commercialization. Bora Biologics said its mission remains focused on helping bring biologic therapies to patients worldwide.
